Long lifetime alpha-hemolysin nanopores
AssigneeRoche Sequencing Solutions, Inc.
InventorsMark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
Life of this patent
Estimating the term…
Loading patent…
AssigneeRoche Sequencing Solutions, Inc.
InventorsMark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
Estimating the term…
Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L1351 in the mature alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
Dependencies are inferred from the claim text.